GT200600253A - Aminopirimidinas como moduladores de quinasas - Google Patents

Aminopirimidinas como moduladores de quinasas

Info

Publication number
GT200600253A
GT200600253A GT200600253A GT200600253A GT200600253A GT 200600253 A GT200600253 A GT 200600253A GT 200600253 A GT200600253 A GT 200600253A GT 200600253 A GT200600253 A GT 200600253A GT 200600253 A GT200600253 A GT 200600253A
Authority
GT
Guatemala
Prior art keywords
compounds
trkb
kit
aminopirimidins
flt3
Prior art date
Application number
GT200600253A
Other languages
English (en)
Inventor
Michael David Gaul
Gouzhang Xu
Christian Andrew Baumann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200600253A publication Critical patent/GT200600253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCFIÓN SE REFIERE A COMPUESTOS DE AMINOPIRIDINA DE LA FÓRMULA (I), DONDE R3, B, Z, R Y R1 SON COMO SE DEFINEN EN LA PRESENTE, AL USO DE TALES COMPUESTOS COMO MODULADORES DE LA PROTEÍNA TIROSINA QUINASA, EN PARTICULAR INHIBIDORES DE FLT3 Y/O C-KIT Y/O TRKB, AL USO DE TALES COMPUESTOS PARA REDUCIR O INHIBIR LA ACTIVIDAD DE QUINASA DE FLT3 Y/O C-KIT Y/O TRKB EN UNA CÉLULA O UN SUJETO, Y AL USO DE TALES COMPUESTOS PARA PREVENIR O TRATAR EN UN SUJETO UN TRASTORNO DE PROLIFERACIÓN CELULAR Y/O TRASTORNOS RELACIONADOS CON FLT3 Y/O C-KIT Y/O TRKB. LA PRESENTE INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN LOS COMPUESTOS DE LA PRESENTE INVENCIÓN Y A MÉTODOS PARA TRATAR CONDICIONES PATOLÓGICAS TALES COMO CÁNCERES Y OTROS TRASTORNOS DE PROLIFERACIÓN CELULAR.
GT200600253A 2005-06-10 2006-06-08 Aminopirimidinas como moduladores de quinasas GT200600253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68971505P 2005-06-10 2005-06-10
US75108305P 2005-12-16 2005-12-16

Publications (1)

Publication Number Publication Date
GT200600253A true GT200600253A (es) 2007-01-12

Family

ID=36930537

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600253A GT200600253A (es) 2005-06-10 2006-06-08 Aminopirimidinas como moduladores de quinasas

Country Status (24)

Country Link
US (1) US20070021435A1 (es)
EP (1) EP1898917B1 (es)
JP (1) JP2008545797A (es)
KR (1) KR20080026592A (es)
AR (1) AR054388A1 (es)
AT (1) ATE420646T1 (es)
AU (1) AU2006258039A1 (es)
BR (1) BRPI0611597A2 (es)
CA (1) CA2611495A1 (es)
CR (1) CR9649A (es)
DE (1) DE602006004873D1 (es)
EA (1) EA200800018A1 (es)
EC (1) ECSP077994A (es)
ES (1) ES2319574T3 (es)
GT (1) GT200600253A (es)
HK (1) HK1116059A1 (es)
IL (1) IL187686A0 (es)
MX (1) MX2007015742A (es)
NI (1) NI200700313A (es)
NO (1) NO20080161L (es)
PE (1) PE20070111A1 (es)
TW (1) TW200716118A (es)
UY (1) UY29591A1 (es)
WO (1) WO2006135719A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
EP1928862A1 (en) * 2005-09-13 2008-06-11 Palau Pharma, S.A. 2-aminopyrimidine derivatives as modulators of the histamine h4 receptor activity
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
WO2013113776A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113716A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113782A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
WO2013113773A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
BR112014018909A8 (pt) 2012-02-03 2017-07-11 Basf Se Compostos, processo para a preparação dos compostos, composição agroquímica, método para o combate dos fungos, utilização dos compostos e semente
WO2013113791A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds
EA201400858A1 (ru) 2012-02-03 2015-01-30 Басф Се Фунгицидные пиримидиновые соединения
WO2013113781A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds i
WO2013113719A1 (en) 2012-02-03 2013-08-08 Basf Se Fungicidal pyrimidine compounds ii
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
WO2013135672A1 (en) 2012-03-13 2013-09-19 Basf Se Fungicidal pyrimidine compounds
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE253915T1 (de) * 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors

Also Published As

Publication number Publication date
EP1898917A1 (en) 2008-03-19
UY29591A1 (es) 2006-10-02
WO2006135719A1 (en) 2006-12-21
CA2611495A1 (en) 2006-12-21
MX2007015742A (es) 2008-04-29
BRPI0611597A2 (pt) 2010-09-21
PE20070111A1 (es) 2007-02-09
ES2319574T3 (es) 2009-05-08
NI200700313A (es) 2009-03-24
AR054388A1 (es) 2007-06-20
AU2006258039A1 (en) 2006-12-21
EA200800018A1 (ru) 2008-06-30
ATE420646T1 (de) 2009-01-15
CR9649A (es) 2008-09-09
NO20080161L (no) 2008-01-28
ECSP077994A (es) 2008-01-23
HK1116059A1 (en) 2008-12-19
EP1898917B1 (en) 2009-01-14
US20070021435A1 (en) 2007-01-25
KR20080026592A (ko) 2008-03-25
JP2008545797A (ja) 2008-12-18
TW200716118A (en) 2007-05-01
IL187686A0 (en) 2008-08-07
DE602006004873D1 (de) 2009-03-05

Similar Documents

Publication Publication Date Title
GT200600253A (es) Aminopirimidinas como moduladores de quinasas
GT200600248A (es) Aminopirimidinas como moduladores de quinasas
UY29588A1 (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina
GT200600254A (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
CR10094A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
TW200621721A (en) Methods of preparing indazole compounds
CL2008001815A1 (es) Compuestos derivados de indazol; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar cancer.
GT200600035A (es) Aminopiridinas como inhibidores de beta-secretasa
BRPI0514537B8 (pt) compostos de aminoeteroarila substituídos com pirazol e composição farmacêutica que os compreende
ECSP109957A (es) Derivados de pirimidinil-piridazinona.
CO6290760A2 (es) Derivados de alcoholes de 1 fenil-2-piridinilalquilo como inbidores de la fosfodiesterasa
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CL2010001415A1 (es) Compuestos derivados de diazacarbazol, con actividad inhibidora de quinasa; composición farmacéutica que comprende a uno de los compuestos; y uso de la composición farmacéutica en la preparación de medicamentos para la inhibición del crecimiento celular o el tratamiento de un trastorno hiperproliferativo
ECSP099426A (es) Compuestos de 4-hidroxi-2-oxo-2,3-dihidro-1,3-benzotiazol-7il para la modulación de la actividad del adrenoreceptor beta2
NI200700311A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de la cinasa de flt-3
CL2011000489A1 (es) Compuestos derivados de pirimido[5,4-d]pirimidina, los cuales actuan como inhibidores de tirosina-quinasas; y composiciones farmaceuticas que los comprenden, utiles en el tratamiento de enfermedades que se caracterizan por una proliferacion celular excesiva o anomala
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения
GT200600250A (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas